Barrow, Hanley, Mewhinney & Strauss’s Bristol-Myers Squibb BMY Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-49,057	Closed	-$3.58M	–	303
2022 Q1	$3.58M	Sell	49,057 -7,958	-14%	-$534K	0.01%	135
2021 Q4	$3.56M	Hold	57,015	–	–	0.01%	148
2021 Q3	$3.37M	Sell	57,015 -1,293	-2%	-$85.2K	0.01%	150
2021 Q2	$3.9M	Sell	58,308 -3,632	-6%	-$237K	0.01%	148
2021 Q1	$3.91M	Sell	61,940 -2,646	-4%	-$165K	0.01%	150
2020 Q4	$4.01M	Buy	64,586 +9,389	+17%	+$577K	0.01%	147
2020 Q3	$3.33M	Sell	55,197 -27,684	-33%	-$1.67M	0.01%	146
2020 Q2	$4.87M	Hold	82,881	–	–	0.02%	140
2020 Q1	$4.62M	Buy	82,881 +115	+0.1%	+$7.03K	0.02%	130
2019 Q4	$5.31M	Sell	82,766 -658,421	-89%	-$37.7M	0.02%	137
2019 Q3	$37.6M	Sell	741,187 -33,390	-4%	-$1.57M	0.07%	130
2019 Q2	$35.1M	Sell	774,577 -25,758	-3%	-$1.2M	0.06%	137
2019 Q1	$38.2M	Buy	+800,335	New	+$39.9M	0.07%	137

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's BMY Position: Q2 2022 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Bristol-Myers Squibb (BMY) in Q2 2022, closing a stake of 49,057 shares — an estimated $3.58M sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in BMY in Q1 2019 and held it in 13 quarters. The position peaked at $38.2M in Q1 2019. 2,537 funds tracked by Wall St. Rank hold BMY as of Q2 2022.

Barrow, Hanley, Mewhinney & Strauss reported no remaining Bristol-Myers Squibb position as of Q2 2022 after selling out during the quarter.
Barrow, Hanley, Mewhinney & Strauss sold 49,057 Bristol-Myers Squibb shares in Q2 2022, an estimated $3.58M.
Barrow, Hanley, Mewhinney & Strauss first reported a position in Bristol-Myers Squibb in Q1 2019 and held it in 13 quarters.
Barrow, Hanley, Mewhinney & Strauss's Bristol-Myers Squibb position peaked at $38.2M in Q1 2019.
2,537 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2022.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q2 2022, filed 11 Aug 2022.